FAQ

DBM is a bone grafting material derived from human or animal bone that has had its minerals removed. It contains growth factors and proteins that promote bone healing and regeneration. Surgeons use DBM in various orthopedic procedures, such as spinal fusion, fracture repair, and bone defect reconstruction.

Yes, all Staysis Medical DBM products are rigorously tested, compliant with FDA regulations, and meet stringent safety standards. Our commitment to quality and safety is paramount in all our offerings.

Healthcare providers can easily order Staysis Medical's DBM products through our online portal or by contacting our customer service team. We offer streamlined ordering processes to ensure efficient delivery and support.

Our DBM products have a validated shelf life of at least two years, ensuring product integrity and efficacy until the expiration date. Detailed storage and handling instructions are provided with each product.

Yes, our DBM products should be stored in a controlled environment with specific temperature and humidity conditions as outlined in the product instructions. Proper storage is essential to maintain product stability and efficacy.

Staysis Medical provides comprehensive support to healthcare providers, including training, education, and clinical resources on the use of DBM in surgical procedures. Our dedicated team is available to assist with any questions or concerns regarding product use and patient care.

Staysis Medical's flowable hemostat stands out for its advanced formulation and best-in-class mixing chamber, ensuring optimal consistency and efficacy in controlling bleeding during surgeries.

Yes, our flowable hemostat is designed for use in a wide range of surgical specialties, including orthopedics, neurosurgery, general surgery, and more, providing versatile hemostatic solutions for healthcare providers.

Our flowable hemostat works rapidly to control bleeding, typically achieving hemostasis within minutes of application, which can help reduce surgical time and improve patient outcomes.

Our flowable hemostat is designed for easy storage and handling. It should be stored according to the instructions provided and prepared for use using the included mixing chamber for optimal results.

No, Staysis Medical's flowable hemostat is not FDA-approved and is currently in further development and testing. We expect to submit for FDA Approval in 2025.

Yes, our flowable hemostat is suitable for use in minimally invasive procedures, providing effective hemostasis in challenging surgical environments with limited access.

Yes, Staysis Medical provides comprehensive training, education, and clinical support for healthcare providers using our flowable hemostat, ensuring safe and effective application in surgical procedures.

Staysis Medical employs a strategic market access approach, collaborating with key stakeholders, payers, and healthcare systems to ensure widespread availability and reimbursement of our bone products across diverse geographic regions.

Yes, Staysis Medical actively participates in value-based agreements and initiatives with payers and healthcare providers to demonstrate the clinical and economic value of our bone products, facilitating broader market access and adoption.

Yes, Staysis Medical conducts and supports clinical research and studies to generate real-world evidence and clinical data demonstrating the safety, efficacy, and value of our bone products, strengthening market access and reimbursement considerations.

Yes, Staysis Medical provides comprehensive educational resources, training programs, and support to healthcare providers, empowering them with knowledge and skills to effectively utilize and advocate for our bone products in clinical practice.

Staysis Medical collaborates closely with healthcare systems and providers through tailored programs, clinical support, and partnership initiatives to optimize the utilization and outcomes of our bone products for the benefit of patients.

Staysis Medical is committed to ongoing innovation, collaboration, and advocacy to enhance market access, improve patient access to our bone products, and drive positive outcomes in orthopedic care across healthcare systems and communities.